Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alzamend Neuro

Alzamend Neuro
2016 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$232K LATEST DEAL AMOUNT
Description

Developer of immunotherapeutic treatment and vaccine designed to treat Alzheimer's diseases. The company's immunotherapeutic treatment and vaccines are cell based therapeutic vaccines which are considered as as an immunotherapy to prevent or slow down Alzheimer's diseases, enabling patients to recover Alzheimer's diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 3802 Spectrum Boulevard
  • Suite 112C
  • Tampa, FL 33612
  • United States

+1 (844) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alzamend Neuro’s full profile, request a free trial.

Alzamend Neuro Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 19-Apr-2019 $232K 00.000 Completed Generating Revenue
2. Angel (individual) 22-Aug-2017 Cancelled Generating Revenue
1. Angel (individual) 01-Jul-2016 $1M $1M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Alzamend Neuro Executive Team (2)

Name Title Board
Seat
Contact
Info
Philip Mansour President, Board Member & Chief Executive Officer
Milton Ault III Founder & Chairman

Alzamend Neuro Board Members (3)

Name Representing Role Since Contact
Info
Milton Ault III Self Founder & Chairman 000 0000
Philip Mansour Alzamend Neuro President, Board Member & Chief Executive Officer 000 0000
William Horne Alzamend Neuro Board Member 000 0000